Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Interferon-Alpha

  • Angela Märten
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_3091-2

Synonyms

Definition

Interferons (IFNs) belong to the group of cytokines and are produced by various cells as part of an immune response to a viral infection or other immune trigger. IFNs are a family of molecules that include more than 15 expressed genes and a number of pseudogenes coded on chromosome 9. IFN-α belongs to the type I IFNs.

Characteristics

IFN-α is produced by monocytes/macrophages, lymphoblastoid cells, fibroblasts, and plasmacytoid dendritic cells(DC). It is detectable under physiological conditions but markedly enhanced during infections, especially viral infections. IFN-α binds to the IFN-α/β receptor CD118; binding to the Epstein–Barr virus receptor CD21 is also described. Binding to the IFN receptor activates the transcription of several different genes inducing the synthesis of host cell proteins that contribute to the inhibition of viral replication. In addition to its antiviral properties, IFN-α...

Keywords

Vascular Endothelial Growth Factor Metastatic Renal Cell Carcinoma Thymidine Phosphorylase Hairy Cell Leukemia Vascular Endothelial Growth Factor Serum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Belardelli F, Ferrantini M, Proietti E (2002) Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:119–134CrossRefPubMedGoogle Scholar
  2. Decatris M, Santhanam S, O’Byrne K (2002) Potential of interferon-alpha in solid tumours: part 1. BioDrugs 16:261–281CrossRefPubMedGoogle Scholar
  3. Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836–848CrossRefPubMedGoogle Scholar
  4. Kirkwood J (2002) Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 29:18–26CrossRefPubMedGoogle Scholar
  5. Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5:375–386CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.National Centre for Tumour Diseases, Heidelberg, Germany; Department of SurgeryUniversity Hospital HeidelbergHeidelbergGermany